Cdc25 as a potential target of anticancer agents

Investigational New Drugs

Volumn 18, Issue 2, 2000, Pages 149-156

  Eckstein, Jens W ^a  

^a Enanta Pharmaceuticals   (United States)

Author keywords

Cancer; Cdc25; Cell cycle regulation; Inhibitors; PTPase

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; ALKYLLYSOPHOSPHOLIPID; ANTINEOPLASTIC AGENT; BUTENOLIDE; DEPHOSTATIN; DNACIN; DYSIDIOLIDE; ETHER LIPID; LACTONE DERIVATIVE; MENADIONE; MENAQUINONE; MILTEFOSINE; PHYTOMENADIONE; POTASSIUM BISPEROXO (1,10 PHENANTROLINE) OXOVANADATE; POTASSIUM BISPEROXO (PYRIDINE 2 CARBOXYLATO) OXOVANDATE; PROTEIN CDC 25; PROTEIN INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; QUINOXALINE DERIVATIVE; RK 682; SESQUITERPENE; STEVASTELIN; SULFIRCIN; TUNGSTEN DERIVATIVE; UNCLASSIFIED DRUG; VANADIC ACID; VANADIUM DERIVATIVE; VITAMIN K GROUP;

CANCER GENETICS; CARCINOGENESIS; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVE SITE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN STRUCTURE; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; FUNGAL PROTEINS; HUMANS; NEOPLASMS; RAS-GRF1;

EID: 0034065868     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006377913494     Document Type: Review

References (62)

1. Russell P, Nurse P: cdc25+ functions as an inducer in the mitotic control of fission yeast. Cell 45(1): 145-153, 1986.
2. Parsons, R: Phosphatases and tumorigenesis. Curr Opin Oncol 10(1): 88-91, 1998
3. Draetta G, Eckstein J: Cdc25 protein phosphatases in cell proliferation. Biochim Biophys Acta 1332(2): M53-M63, 1997
4. Eckstein J: Cdc25 protein phosphatase: regulation and its role in cancer Gene Ther Mol Biol 1: 707-711, 1998
5. Pines J: Cell cycle. Checkpoint on the nuclear frontier. Nature 397(6715): 104-105, 1999
6. Zornig M, Evan GI: Cell cycle: on target with Myc. Curr Biol 6(12): 1553-1556, 1996
7. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, Beach D: CDC25 phosphatases as potential human oncogenes. Science 269(5230): 1575-1577, 1995
8. Gasparotto D, Maestro R, Piccinin S, Vukosavljevic T, Barzan L, Sulfaro S, Boiocchi M: Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res 57(12): 2366-2368, 1997
9. Hernandez S, Hernandez L, Bea S, Cazorla M, Fernandez PL, Nadal A, Muntane J, Mallofre C, Montserrat E, Cardesa A, Campo E: cdc25 cell cycle-activating phosphatases and c-myc expression in human nonHodgkin's lymphomas. Cancer Res 58(8): 1762-1767, 1998
10. Galaktionov K, Chen X, Beach D: Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382(6591): 511-517, 1996
11. Kudo Y, Yasui W, Ue T, Yamamoto S, Yokozaki H, Nikai H, Tahara E: Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn J Cancer Res 88(10): 947-952, 1997
12. Wu W, Fan YH, Kemp BL, Walsh G, Mao L: Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res 58(18): 4082-4085, 1998
13. Robinson SP, Perron D, Miller R, Parker L, Johnston C, Wei F-Y, Jin P, Tam S, Worland P, Wickramsinghe D, Voss J: Elevated levels of Cdc25 A and C in human tumour cell lines. Proc Amer Assoc Cancer Res 40: #79, 1999
14. Russell P: Checkpoints on the road to mitosis. TIBS 23: 399-402, 1998
15. Furnari B, Rhind N, Russell P: Cdc25 mitotic inducer targeted by chkl DNA damage checkpoint kinase (see comments). Science 277(5331): 1495-1497, 1997
16. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ: Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25 (see comments). Science 277(5331): 1497-1501, 1997
17. Zeng Y, Forbes KC, Wu Z, Moreno S, Piwnica-Worms H, Enoch T: Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cdsl or Chk1. Nature 395(6701): 507-510, 1998
18. Kumagai A, Yakowec PS, Dunphy WG: 14-3-3 proteins act as negative regulators of the mitotic inducer Cdc25 in Xenopus egg extracts. Mol Biol Cell 9(2): 345-354, 1998
19. Lopez-Girona A, Furnari B, Mondesert O, Russell P: Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein (see comments). Nature 397(6715): 172-175, 1999
20. Peng CY, Graves PR, Ogg S, Thoma RS, Byrnes MJ, 3rd, Wu Z, Stephenson MT, Piwnica-Worms H: C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding. Cell Growth Differ 9(3): 197-208, 1998
21. Wickramasinghe D, Palka ME, Reid S, Tessarollo L, Donovan PJ: The role of Cdc25B during mouse development. Keystone Symposia on Growth Control Abstract: 147, 1997
22. Ashcroft NR, Kosinski ME, Wickramasinghe D, Donovan PJ, Golden A: The four cdc25 genes from the nematode Caenorhabditis elegans. Gene 214(1-2): 59-66, 1998
23. Ashcroft NR, Srayko M, Kosinski ME, Mains PE, Golden A: RNA-Mediated interference of a cdc25 homolog in Caenorhabditis elegans results in defects in the embryonic cortical membrane, meiosis, and mitosis. Dev Biol 206(1): 15-32, 1999
24. Galaktionov K and Beach D: Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell 67(6): 1181-1194, 1991
25. Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H, Okayama H: Cdc25A is a novel phosphatase functioning early in the cell cycle. Embo J 13(7): 1549-1556, 1994
26. Hoffmann I, Draetta G, Karsenti E: Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the GI /S transition. Embo J 13(18): 4302-4310, 1994
27. Garner-Hamrick PA, Fisher C: Antisense phosphorothioate oligonucleotides specifically down-regulate cdc25B causing S-phase delay and persistent antiproliferative effects. Int J Cancer 76(5): 720-728, 1998
28. Fauman EB, Cogswell JP, Lovejoy B, Rocque WJ, Holmes W, Montana VG, Piwnica-Worms H, Rink MJ, Saper MA: Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A. Cell 93(4): 617-625, 1998
29. Walker N, Borhani D, Fujimori T, Bettencourt B, Taylor, Neil, Rudolph J, Epstein D, Bottomley S, Eckstein JW: The crystal structure of a catalytic domain of human Cdc25. unpublished, 1997
30. Fauman EB, Saper MA: Structure and function of the protein tyrosine phosphatases. Trends Biochem Sci 21(11): 413-417, 1996
31. Eckstein JW, Beer-Romero P, Berdo I: Identification of an essential acidic residue in Cdc25 protein phosphatase and a general three-dimensional model for a core region in protein phosphatases. Protein Sci 5(1): 5-12, 1996
32. Stuckey JA, Schubert HL, Fauman EB, Zhang ZY, Dixon JE, Saper MA: Crystal structure of Yersinia protein tyrosine phosphatase at 2.5 A and the complex with tungstate (see comments). Nature 370(6490): 571-575, 1994.
33. Hofmann K, Bucher P, Kajava AN: A model of Cdc25 phosphatase catalytic domain and Cdk-interaction surface based on the presence of a rhodanese homology domain. J Mol Biol 282(1): 195-208, 1998
34. Gottlin EB, Xu X, Epstein DM, Burke SP, Eckstein JW, Ballou DP, Dixon JE: Kinetic analysis of the catalytic domain of human cdc25B. J Biol Chem 271(44): 27445-27449, 1996
35. Eckstein JW: From sequence to function - structural motifs of cell cycle proteins., in Cell Cycle - Materials and Methods, M. Pagano, Editor. Springer: Berlin/Heidelberg/New York. 186-199, 1995
36. Fauman EB, Yuvaniyama C, Schubert HL, Stuckey JA, Saper MA: The X-ray crystal structures of Yersinia tyrosine phosphatase with bound tungstate and nitrate. Mechanistic implications. J Biol Chem 271 (31): 18780-18788, 1996
37. Faure R, Vincent M, Dufour M, Shaver A, Posner BI: Arrest at the G2/M transition of the cell cycle by protein-tyrosine phosphatase inhibition: studies on a neuronal and a glial cell line. J Cell Biochem 59(3): 389-401, 1995
38. Imoto M, Kakeya H, Sawa T, Hayashi C, Hamada M, Takeuchi T, Umezawa K: Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces. 1. Taxonomy, isolation, and characterization (published erratum in J Antibiot (Tokyo) 1994 Feb;47(2):C-1). J Antibiot (Tokyo) 46(9): 1342-1346, 1993
39. Caselli A, Camici G, Manao G, Moneti G, Pazzagli L, Cappugi G, Ramponi G: Nitric oxide causes inactivation of the low molecular weight phosphotyrosine protein phosphatase. J Biol Chem 269(40): 24878-24882, 1994
40. Caselli A, Chiarugi P, Camici G, Manao G, Ramponi G: In vivo inactivation of phosphotyrosine protein phosphatases by nitric oxide. FEBS Lett 374(2): 249-252, 1995
41. Wright AE, McCarthy PJ, Schulte GK: Sulfircin: A new sesterterpene sulfate from a deep-water sponge of the genus Ircinia. J Org chem (54): 3472-3474, 1989
42. Cebula RE, Blanchard JL, Boisclair MD, Mansuri MM, Pal K, Bockovich NJ: Synthesis and phosphatase activity of analogs of sulfircin. Bioorg Med Chem Letters 7: 2015-2020, 1997
43. Burke TR Jr, Zhang ZY: Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery. Biopolymers 47(3): 225-241, 1998
44. Kole HK, Akamatsu M, Ye B, Yan X, Barford D, Roller PP, Burke TR Jr: Protein-tyrosine phosphatase inhibition by a peptide containing the phosphotyrosyl. mimetic, L-O-malonyltyrosine. Biochem Biophys Res Commun 209(3): 817-822, 1995
45. Groves MR, Yao ZJ, Roller PP, Burke TR Jr, Barford D: Structural basis for inhibition of the protein tyrosine phos phatase IB by phosphotyrosine peptide mimetics. Biochemistry 37(51): 17773-17783, 1998
46. Morino T, Shimada K, Masuda A, Yamashita N, Nishimoto M, Nishikiori T, Saito S: Structural determination of stevastelins, novel depsipeptides from Penicillium s J Antibiot (Tokyo) 49(6): 564-568, 1996
47. Horiguchi T, Nishi K, Hakoda S, Tanida S, Nagata A, Okayama H: Dnacin Al and dnacin B1 are antitumor antibiotics that inhibit cdc25B phosphatase activity. Biochem Pharmacol 48(11): 2139-2141, 1994
48. Hamaguchi T, Sudo T, Osada H: RK-682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at Glphase. FEBS Lett 372(1): 54-58, 1995
49. Ni R, Nishikawa Y, Carr BI: Cell growth inhibition by a novel vitamin K is associated with induction of protein tyrosine phosphorylation. J Biol Chem 273(16): 9906-9911, 1998
50. Gunasekera SP, McCarthy PJ, Kelly-Borges M: Dysidiolide: A novel protein phosphatase inhibitor from the Caribbean sponge Dysidea etheria de Laubenfels. J Am Chem Soc 118: 8795-8796, 1996
51. Blanchard JL, Epstein DM, Boi clair M, Rudolph J, Eckstein J, Pal K: Dysidiolide and Related γ-hydroxy Butenolide Inhibitors of the Human Dual Specificity Protein-Tyrosine Phosphatase Cdc25. Bioorg Med Chem Letters, 1999, in press
52. Peng H, Zalkow LH, Abraham RT, Powis G: Novel CDC25A Phosphatase Inhibitors from Pyrolysis of 3-a-Azido-B-homo-6-oxa-4-cholesten-7-one on Silica Gel J Med Chem 41(24): 4677-4680, 1998
53. Koufaki M, Polychroniou V, Calogeropoulou T, Tsotinis A, Drees M, Fiebig HH, LeClerc S, Hendriks HR, Makriyannis A: Alkyl and alkoxyethyl antineoplastic phospholipids. J Med Chem 39 (13): 2609-2614, 1996
54. Ham SW, Park J, Lee SJ, Kim W, Kang K, Choi KH: Naphthoquinone analogs as inactivators of cdc25 phosphatase. Bioorg Med Chem Lett 8(18): 2507-2510, 1998
55. el-Subbagh HI, Abadi AH, al-Khawad IE, al-Rashood KA: Synthesis and antitumor activity of some new substituted quinolin-4-one and 1,7-naphthyridin-4-one analogs. Arch Pharm (Weinheim) 332(1): 19-24, 1999
56. Abadi AH: 5-substituted 2-bromoindolo(3,2-blquinoxalines- A class of potential antitumor agents with cdc25 phosphatase inhibitory properties. Arch Pharm (Weinheim) 331(11): 352-358, 1998
57. Moran EJ, Sarshar S, Cargill JF, Shahbaz MM, Lio A, Mjalli AMM, Armstrong R: Radio frequency tag encoded combinatorial library method for the discovery of tripeptide-substituted cinnamic acid inhibitors of protein tyrosine phosphatase PTP1B. J Am Chem Soc 117: 10787-10788, 1995
58. Rice RL, Rusnak JM, Yokokawa F, Yokokawa S, Messner DJ, Boynton AL, Wipf P, Lazo JS: A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation. Biochemistry 36(50): 15965-15974, 1997
59. Posner BI, Faure R, Burgess JW, Sevan AP, Lachance D, ZhangSun G, Fantus IG, Ng JB, Hall DA, Lum BS, Shaver A: Peroxovanadium. Compounds: A new class of potent phosphotyrosine inhibitors which are insulin mimetics. J Biol Chem 269(6): 4596-4604, 1994
60. Suttie JW: Synthesis of vitamin K-dependent proteins. FASEB J 7(5): 445-452, 1993
61. Juan CC, Wu FY: Vitamin K3 inhibits growth of human hepatoma HepG2 cells by decreasing activities of both p34cdc2 kinase and phosphatase. Biochem Biophys Res Commun 190(3): 907-913, 1993
62. Unger C, Damenz W, Fleer EAM, Kim DJ, Breiser A, Hilgard P, Engel J, Nagel G, Eibl H: Hexadecylphosphocholine, a new ether lipid analogue. Acta Oncol 28: 213-217, 1989